A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for understanding and treating Duchenne Muscular Dystrophy (DMD).
Categories
Recent Posts
- FDA authorizes a new liver safety biomarker relevant for Duchenne and Becker
- FDA approves new safety warning and updated prescribing information for Sarepta’s Elevidys
- Insmed’s ASCEND Study and INS1201, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
- Progress Now: Immunotherapy Study Recruiting, Drug Cleared for Expanded Access, and More
- From Classroom to Courtroom: How Eric Arnold Navigated Accessibility in His Education and Career